Pharmaceuticals and vector-control programmes have greatly diminished the once-widespread disease, but sustained effort will ...

Patients with presbyopia experienced improvements in near vision after treatment with Brimochol PF in a second phase 3 ...

LONDON, Jan. 7, 2025 /PRNewswire/ -- Norgine today announced that it completed its marketing authorisation application filing ...

PAH is a rare condition in children, but is often fatal if left untreated, and protocols for pediatric patients have not been ...

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European Medicines Agency (EMA) for ...

Actuate Therapeutics (ACTU) announced that the European Medicines Agency, EMA, has granted Orphan Medicinal Product Designation, OMPD, to ...

After nearly a decade of machine learning innovations, the FDA has issued its first draft guidance on the use of AI in drug ...

Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the ...

With limited treatment options available for patients with PDAC, the EMA Orphan Drug Designation and FDA Orphan Drug Designation granted to elraglusib for the same indication reflect elraglusib’s ...

Among the health policy novelties of 2025, a new tool developed by the European Medicines Agency (EMA) is set to harmonise ...